Keywords
Palmoplantar pustulosis, baricitinib, rheumatoid arthritis, cutaneous side effects
Abstract
Objectives: Baricitinib is an orally active Janus kinase (JAK) inhibitor used in the treatment of moderate to severe rheumatoid arthritis (RA).
Materials and methods: Here, we report the case of a 56-year-old Caucasian male diagnosed with RA who developed palmoplantar pustulosis (PPP) while being treated with baricitinib.
Results: The patient’s PPP resolved after discontinuation of baricitinib and recurred when this was restarted. Based on causality assessment, it was considered a drug-induced PPP. Conclusion: To the authors’ knowledge, this is the first case of baricitinib-induced PPP.
References
Views: 2006
HTML downloads: 268
PDF downloads: 744
Published:
2019-12-19
Issue:
2020: Vol 7 No 1
(view)